AVGO vs SONM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.
The company exhibits extreme financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental health. With a Quick Ratio of 0.03 and a negative Price-to-Book ratio of -4.35, the firm is facing a severe liquidity crisis and possesses negative shareholders' equity. Catastrophic Q/Q revenue growth of -394.48% and a 5-year price decline of 99.7% suggest a business in terminal decline. The lack of an Altman Z-Score calculation is likely due to the absence of positive working capital or equity, further signaling insolvency risk.
Compare Another Pair
Related Comparisons
AVGO vs SONM: Head-to-Head Comparison
This page compares Broadcom Inc. (AVGO) and DNA X, Inc. (SONM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.